Exelixis, Inc.
General ticker "EXEL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $10.3B (TTM average)
Exelixis, Inc. follows the US Stock Market performance with the rate: 30.3%.
Estimated limits based on current volatility of 1.2%: low 43.67$, high 44.70$
Factors to consider:
- Total employees count: 1147 (-12.4%) as of 2024
- US accounted for 84.1% of revenue in the fiscal year ended 2025-01-03
- Top business risk factors: Inability to maintain sales and marketing capabilities, Labor/talent shortage/retention, Market competition, Cybersecurity threats, Acquisition/divestiture risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-01-03 to 2027-01-03
- 2025-01-03 to 2026-01-03 estimated range: [27.23$, 43.55$]
- 2026-01-03 to 2027-01-03 estimated range: [26.39$, 42.63$]
Financial Metrics affecting the EXEL estimates:
- Positive: with PPE of 17.9 at the end of fiscal year the price was low
- Positive: Operating profit margin, % of 27.88 > 18.64
- Positive: Return on assets ratio (scaled to [-100,100]) of 15.03 > 6.04
- Negative: negative Industry operating cash flow (median)
- Positive: 6.82 < Operating cash flow per share per price, % of 7.15
- Positive: Shareholder equity ratio, % of 76.13 > 63.39
- Negative: negative Industry operating income (median)
- Positive: -4.48 < Investing cash flow per share per price, % of -1.19
Short-term EXEL quotes
Long-term EXEL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2025-01-03 |
|---|---|---|---|
| Operating Revenue | $1,611.06MM | $1,830.21MM | $2,168.70MM |
| Operating Expenses | $1,409.58MM | $1,659.32MM | $1,564.08MM |
| Operating Income | $201.48MM | $170.88MM | $604.62MM |
| Non-Operating Income | $32.87MM | $86.64MM | $77.02MM |
| R&D Expense | $891.81MM | $1,044.07MM | $910.41MM |
| Income(Loss) | $234.35MM | $257.52MM | $681.64MM |
| Taxes | $52.07MM | $49.76MM | $160.37MM |
| Profit(Loss)* | $182.28MM | $207.76MM | $521.27MM |
| Stockholders Equity | $2,488.43MM | $2,263.91MM | $2,244.20MM |
| Inventory | $33.30MM | $17.32MM | $22.39MM |
| Assets | $3,071.49MM | $2,942.36MM | $2,947.69MM |
| Operating Cash Flow | $362.61MM | $333.32MM | $699.97MM |
| Capital expenditure | $138.46MM | $162.97MM | $66.19MM |
| Investing Cash Flow | $-524.41MM | $-26.95MM | $-116.78MM |
| Financing Cash Flow | $0.59MM | $-546.05MM | $-628.81MM |
| Earnings Per Share** | $0.57 | $0.65 | $1.80 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.